Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

34.21 -0.23 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 308,493
Open 35.00
Bid (Size) 32.50 (2)
Ask (Size) 35.10 (1)
Prev. Close 34.44
Today's Range 33.55 - 35.41
52wk Range 32.37 - 76.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Analyst Expectations For Immunocore Hldgs's Future
Via Benzinga

Performance

YTD
-52.25%
-52.25%
1 Month
-7.26%
-7.26%
3 Month
-2.59%
-2.59%
6 Month
-45.61%
-45.61%
1 Year
-33.33%
-33.33%

More News

Read More
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
The Latest Analyst Ratings For Immunocore Hldgs
Via Benzinga
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
3 Small-Cap Stocks with Significant Growth Potential
Via InvestorPlace
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
Via Benzinga
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Analyst Expectations For Immunocore Hldgs's Future
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.